The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.

AstraZeneca’s sBLA submission is supported by outcomes from a multi-centre Phase III trial. Credit: © AstraZeneca 2024. · Pharmaceutical Technology ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

Muscle invasive bladder cancer (MIBC) is an advanced stage of bladder cancer that invades the smooth muscle lining of the bladder. Bladder cancer typically originates in the urothelium, which is a ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic ...

Effect of GemRIS (gemcitabine-releasing intravesical system, TAR-200) on antitumor activity in muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting ...

G_bladder_cancer_micrograph Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at ...

The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested. Survival outcomes improve with 4 cycles of neoadjuvant gemcitabine plus ...

Muscle invasive bladder cancer (MIBC) is a type of transitional cell carcinoma that originates from the urothelium and gradually invades the detrusor muscle of the urinary bladder. MIBC is an advanced ...